To make the study even more relevant to the situation of patients already in the malignant phase of hypertension, we also examined if the treatment would attenuate hypertension and end-organ damage in our Cyp1a1-Ren-2 transgenic rats at the established malignant phase. Here, CYP1A1 is linked to Hypertension.